Eiger BioPharmaceuticals shares are trading lower after the company announced its decision to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta.
Portfolio Pulse from Benzinga Newsdesk
Eiger BioPharmaceuticals has decided to discontinue its Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta, causing its shares to trade lower.
September 13, 2023 | 12:24 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eiger BioPharmaceuticals' decision to discontinue its Phase 3 study has led to a decrease in its share prices.
The discontinuation of a Phase 3 study is a significant event for a pharmaceutical company, as it indicates a setback in the development of a potential product. This news is likely to negatively impact investor sentiment, leading to a decrease in Eiger BioPharmaceuticals' share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100